Supporters of the NCCN Global Program

NCCN gratefully acknowledges the support and commitment of the following companies to the improvement of the treatments available to the patients whom we all serve. We also appreciate the recognition of NCCN's necessary autonomy in all decision-making regarding the conclusions, recommendations and outcomes of NCCN programs and resources.

Global Corporate Council

The NCCN Global Corporate Council is an important resource for the development and expansion of NCCN programs and resources.

The next NCCN Global Corporate Council Meeting will be held as a live webinar on Thursday, 17 September 2020. More information will be provided as it becomes available.

NCCN offers membership into the NCCN Global Corporate Council to significantly enhance collaborative efforts between pharmaceutical and biotechnical companies and NCCN, and thus better serve patients. NCCN gratefully acknowledges the support and commitment of the following companies through NCCN Global Corporate Council:

  • amgen118
  • astellas118
  • astraZen118
  • bayer118
  • BeiGene-118x40
  • daiichi-sankyo-118x36
  • BoehringerGlobal118
  • genomic-118x24
  • incyte-118x85
  • janssen118
  • lilly118
  • merck-kgaa118x40
  • myriad118
  • novarts118
  • oncopeptides-118x118
  • regeneron118
  • roche118
  • sanofi-118
  • Seagen118
  • Servier118x72
  • takeda-118x59

NCCN is grateful for the support of our US NCCN Corporate Council Members. To view a full list of NCCN Corporate Council Members, click here.

General Mission Support

NCCN is seeking general mission support for its mission-related international work. General Mission Support can be specified by region, program, and/or disease type.

  • Janssen supported NCCN’s mission work in Sub-Saharan Africa. General Mission Support has empowered NCCN to proactively develop global programs that have huge impact in resource constrained populations in Africa.
  • Merck KGaA, Darmstadt, Germany supported NCCN’s Mission work related to global patient advocacy engagement.
  • Takeda Oncology supported NCCN’s global general mission specific to translation of NCCN Content. NCCN was able to continue the translation, verification, and subsequent maintenance/updates of several NCCN Guidelines into multiple languages, including Spanish, Portuguese, Chinese, South Korean, French, German, and Italian.

Opportunities for Collaboration and Sponsorship are available!